BACKGROUND: This study aimed to determine whether the neutrophil-to-lymphocyte ratio (NLR) reflected poor treatment benefits in patients with tumor proportion score (TPS) ≥50% and who under went first-line pembrolizumab monotherapy. PATIENTS AND METHODS: This study retrospectively analyzed patients with untreated stage III/IV or recurrent non-small cell lung cancer (NSCLC) with TPS ≥50% and who received pembrolizumab monotherapy at two hospitals between February 2017 and April 2019. The NLR was calculated from pre-treatment complete blood counts. RESULTS: A total of 51 previously untreated patients with NSCLC who had TPS ≥50% and who underwent pembrolizumab monotherapy were evaluated. Multivariate analysis revealed that high NLR, Eastern Cooperative Oncology Group performance status (PS) ≥2, stage IV or recurrent cancer, and TPS=50-74% were significantly and independently associated with poor progression-free survival. Moreover, high NLR and PS ≥2 were significantly associated with short overall survival. CONCLUSION: A high pre-treatment NLR was associated with significantly short progression-free and overall survival in previously untreated patients with NSCLC with high expression of programmed cell-death ligand 1 treated with pembrolizumab monotherapy. Copyright
BACKGROUND: This study aimed to determine whether the neutrophil-to-lymphocyte ratio (NLR) reflected poor treatment benefits in patients with tumor proportion score (TPS) ≥50% and who under went first-line pembrolizumab monotherapy. PATIENTS AND METHODS: This study retrospectively analyzed patients with untreated stage III/IV or recurrent non-small cell lung cancer (NSCLC) with TPS ≥50% and who received pembrolizumab monotherapy at two hospitals between February 2017 and April 2019. The NLR was calculated from pre-treatment complete blood counts. RESULTS: A total of 51 previously untreated patients with NSCLC who had TPS ≥50% and who underwent pembrolizumab monotherapy were evaluated. Multivariate analysis revealed that high NLR, Eastern Cooperative Oncology Group performance status (PS) ≥2, stage IV or recurrent cancer, and TPS=50-74% were significantly and independently associated with poor progression-free survival. Moreover, high NLR and PS ≥2 were significantly associated with short overall survival. CONCLUSION: A high pre-treatment NLR was associated with significantly short progression-free and overall survival in previously untreated patients with NSCLC with high expression of programmed cell-death ligand 1 treated with pembrolizumab monotherapy. Copyright
Authors: Doran Ksienski; Elaine S Wai; Deepu Alex; Nicole S Croteau; Ashley T Freeman; Angela Chan; Tiffany Patterson; Melissa Clarkson; Leathia Fiorino; Zia Poonja; David Fenton; Sarah Irons; Mary Lesperance Journal: Transl Lung Cancer Res Date: 2021-01
Authors: Martin A Cheever; Suzanne L Topalian; Paul Nghiem; Shailender Bhatia; Evan J Lipson; William H Sharfman; Ragini R Kudchadkar; Andrew S Brohl; Philip A Friedlander; Adil Daud; Harriet M Kluger; Sunil A Reddy; Brian C Boulmay; Adam Riker; Melissa A Burgess; Brent A Hanks; Thomas Olencki; Kari Kendra; Candice Church; Tomoko Akaike; Nirasha Ramchurren; Michi M Shinohara; Bob Salim; Janis M Taube; Erin Jensen; Mizuho Kalabis; Steven P Fling; Blanca Homet Moreno; Elad Sharon Journal: J Immunother Cancer Date: 2021-04 Impact factor: 13.751